Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Akalin, Altuna Dr. (1) Berruezo Llacuna, Maria (1) Daumke, Oliver Prof. Dr. (1) Di Virgilio, Michela Prof. Dr. (1) Driesner, Madlen (1) Gerhardt, Holger Prof. Dr. (1) Gerlach, Kerstin (1) Graf, Robin Dr. (2) Hinz, Michael Dr. (3) Höpken, Uta Elisabeth PD Dr. (19) Kammertöns, Thomas Dr. (1) Keller, Lisa (1) Keller, Ulrich Dr. med. (2) Kocks, Christine Dr. (1) Kolesnichenko, Marina Dr. (1) Leutz, Achim Prof. Dr. (1) Mertins, Philipp Dr. (1) Müller, Gerd Dr. (2) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (2) Popp, Oliver Dr. (1) Prigione, Alessandro Prof. Dr. (1) Rajewsky, Klaus Prof. Dr. (1) Rehm, Armin Dr. (6) Scheidereit, Claus Prof. Dr. (4) Schmidt-Ullrich, Ruth Dr. (1) Wolf, Jana Prof. Dr. (1) Wollert-Wulf, Brigitte (1) Yilmaz, Zekiye Buket Dr. (1) (-) Janz, Martin Dr. (9) (-) Mathas, Stephan Dr. (15) Bioinformatics and Omics Data Science (1) (-) Biologie maligner Lymphome (21) Entwicklung Mechanismus-basierter Krebstherapien (2) Genomdiversifikation & Integrität (1) (-) Mikroumgebung als Regulator bei Autoimmunität und Krebs (1) Molekulare Immunologie und Gentherapie (14) Proteomforschung und molekulare Mechanismen bei neurodegenerativen Erkrankungen (1) Systembiologie von Gen-regulatorischen Elementen (1) Translationale Tumorimmunologie (1) 1999 (2) 2000 (2) 2001 (1) (-) 2002 (6) 2003 (3) 2004 (3) 2005 (3) 2006 (5) (-) 2007 (4) 2008 (4) 2009 (4) 2010 (3) 2011 (4) 2012 (2) 2013 (3) 2014 (2) (-) 2015 (5) 2016 (3) 2017 (5) 2018 (1) 2019 (2) (-) 2020 (6) 2021 (4) 2022 (7) 2023 (10) 2024 (2) 21 Ergebnisse: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner LymphomeMikroumgebung als Regulator bei Autoimmunität und Krebs2002200720152020 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. April 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou 01. März 2007 / Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto 01. Mai 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas 01. Oktober 2007 / Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas 01. November 2002 / Blood In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway M. Chatterjee D. Hoenemann S. Lentzsch K. Bommert C. Sers P. Herrmann S. Mathas B. Doerken R.C. Bargou 02. September 2002 / J Exp Med Nuclear factor κB-dependent gene expression profiling of Hodgkins disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity M. Hinz P. Lemke I. Anagnostopoulos C. Hacker D. Krappmann S. Mathas B. Doerken M. Zenke H. Stein C. Scheidereit 01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer 15. April 2002 / Blood Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease F. Jundt K. Kley I. Anagnostopoulos K. Schulze-Proebsting A. Greiner S. Mathas C. Scheidereit T. Wirth H. Stein B. Doerken 01. Mai 2002 / Blood Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma F. Jundt I. Anagnostopoulos R. Foerster S. Mathas H. Stein B. Doerken 01. August 2002 / EMBO J Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B S. Mathas M. Hinz L. Anagnostopoulos D. Krappmann A. Lietz F. Jundt K. Bommert F. Mechta-Grigoriou H. Stein B. Dörken C. Scheidereit Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Nächste Seite Next › Letzte Seite Last »
01. April 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou
01. März 2007 / Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto
01. Mai 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas
01. Oktober 2007 / Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas
01. November 2002 / Blood In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway M. Chatterjee D. Hoenemann S. Lentzsch K. Bommert C. Sers P. Herrmann S. Mathas B. Doerken R.C. Bargou
02. September 2002 / J Exp Med Nuclear factor κB-dependent gene expression profiling of Hodgkins disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity M. Hinz P. Lemke I. Anagnostopoulos C. Hacker D. Krappmann S. Mathas B. Doerken M. Zenke H. Stein C. Scheidereit
01. Januar 2002 / Int J Cancer Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 M. Janz N. Harbeck P. Dettmar U. Berger A. Schmidt K. Juerchott M. Schmitt H.D. Royer
15. April 2002 / Blood Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease F. Jundt K. Kley I. Anagnostopoulos K. Schulze-Proebsting A. Greiner S. Mathas C. Scheidereit T. Wirth H. Stein B. Doerken
01. Mai 2002 / Blood Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma F. Jundt I. Anagnostopoulos R. Foerster S. Mathas H. Stein B. Doerken
01. August 2002 / EMBO J Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B S. Mathas M. Hinz L. Anagnostopoulos D. Krappmann A. Lietz F. Jundt K. Bommert F. Mechta-Grigoriou H. Stein B. Dörken C. Scheidereit